Recursion Pharmaceuticals (RXRX) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.
The company said that a "confirmed durable partial response" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.
Four of the patients achieved a "best response of stable disease" in multiple dose levels for up to six months of treatment, the company said.
Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。